Q-omics provides the consensus-scored ADTRP profile across patient tissues and cancer cell-line models. ADTRP expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, ADTRP is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, ADTRP RNA expression shows 14,694 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight STAD, COAD, and TGCT as cancer lineages where ADTRP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADTRP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADTRP survival associations across molecular data types. ADTRP RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADTRP RNA expression–survival associations across cancer types. High ADTRP expression shows unfavorable associations in STAD, KIRP, HNSC, KIRC, ACC and GBM. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for ADTRP RNA expression.
This table summarizes ADTRP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ADTRP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADTRP shows lower tumor expression in COAD, KIRP, LUAD and KIRC and higher tumor expression in HNSC and THCA. The COAD box plot shows higher ADTRP RNA expression in normal versus tumor tissue (log2 FC = −4.189, t-test p < 0.001).
This table shows molecular features associated with ADTRP in patient tissues and cancer cell lines. In patient samples, ADTRP shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ADTRP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BONE and LIVER.
